AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19031070 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (15 mg)
Number of subjects: 30
Study 19031070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 17298105 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine 5mg
Number of subjects: 137
Study 17298105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study 15155114 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (20 microg subcutaneous daily)
Number of subjects: 0
Study 15155114 — intervention group
Group type: COMPARATOR
Intervention: Teriparatide
Number of subjects: 0
Study 11369904 — intervention group
Group type: EXPERIMENTAL
Intervention: BCX-34 dermal cream 1%
Number of subjects: 90
Study 11369904 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream (placebo)
Number of subjects: 90
Study 9402450 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of felodipine to metoprolol
Number of subjects: 363
Study 9402450 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacement of metoprolol by felodipine
Number of subjects: 363
Study 9402450 — intervention group
Group type: COMPARATOR
Intervention: Continuation of metoprolol (control)
Number of subjects: 363
Study 9402450 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine monotherapy
Number of subjects: 363
Study 8214490 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl (0.027 mg)
Number of subjects: 112
Study 8214490 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fentanyl (0.027 mg)
Number of subjects: 112
Study 2884225 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 2884225 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 0
Study 2884225 — intervention group
Group type: COMPARATOR
Intervention: Nadolol
Number of subjects: 0
Study 2884225 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 0
Study 2884225 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28124444 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention (CBT) combined with treatment-as-usual (TAU), weekly sessions for 3 months
Number of subjects: 60
Study 28124444 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 60
Study 26850232 — intervention group
Group type: EXPERIMENTAL
Intervention: Video Laryngoscopy (VL) using C-MAC device
Number of subjects: 198
Study 26850232 — intervention group
Group type: COMPARATOR
Intervention: Direct Laryngoscopy (DL) using C-MAC device
Number of subjects: 198
Study 23826742 — intervention group
Group type: EXPERIMENTAL
Intervention: Finely ground maize (Fg) diet (0.5 mm)
Number of subjects: 12
Study 23826742 — intervention group
Group type: COMPARATOR
Intervention: Control diet (Ct) (1.0 mm)
Number of subjects: 12
Study 22452928 — intervention group
Group type: EXPERIMENTAL
Intervention: Wood smoke exposure (14, 220, or 354 μg/m3 for 3 hours)
Number of subjects: 20
Study 22452928 — intervention group
Group type: EXPERIMENTAL
Intervention: Wood smoke exposure
Number of subjects: 20
Study 22452928 — intervention group
Group type: COMPARATOR
Intervention: Clean air exposure
Number of subjects: 20
Study 19758373 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-helminthic therapy
Number of subjects: 1566
Study 19758373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1566
Study 17701027 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 78
Study 17701027 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 78
Study 17701027 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 78
Study 17701027 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 78
Study 17701027 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 78
Study 16223392 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine 2 ml with epinephrine (5 microg/ml)
Number of subjects: 108
Study 16223392 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine 4 ml with epinephrine (2.5 microg/ml)
Number of subjects: 108
Study 16223392 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine 4 ml with epinephrine (5 microg/ml)
Number of subjects: 108
Study 16223392 — intervention group
Group type: COMPARATOR
Intervention: 1% lidocaine 4 ml (no epinephrine)
Number of subjects: 108
Study 12139219 — intervention group
Group type: EXPERIMENTAL
Intervention: Dengue tetravalent live-attenuated vaccine (two doses, given six months apart)
Number of subjects: 59
Study 12139219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 10557952 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose inhaled budesonide
Number of subjects: 0
Study 10557952 — intervention group
Group type: COMPARATOR
Intervention: Standard oral prednisone
Number of subjects: 0
Study 8824656 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐ASA 1.5 g b.d.
Number of subjects: 286
Study 8824656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 286
Study 2285294 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of cephradine every 12 h for 7 days
Number of subjects: 88
Study 2285294 — intervention group
Group type: COMPARATOR
Intervention: 375 mg of amoxicillin‐clavulanate every 8 h for 7 days
Number of subjects: 88
Study 7041936 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 1 mg + Paracetamol 1000 mg
Number of subjects: 120
Study 7041936 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 1.5 mg + Paracetamol 1000 mg
Number of subjects: 120
Study 7041936 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 2 mg + Paracetamol 1000 mg
Number of subjects: 120
Study 7041936 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol 1000 mg alone
Number of subjects: 120
Study 30819707 — intervention group
Group type: EXPERIMENTAL
Intervention: Online, computerised memory specificity training (c-MeST) programme for 2 weeks
Number of subjects: 0
Study 30819707 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 0
Study 28291545 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (B) + single agent chemotherapy (CT)
Number of subjects: 0
Study 28291545 — intervention group
Group type: COMPARATOR
Intervention: Single agent chemotherapy (CT)
Number of subjects: 0
Study 25565364 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination (FDC) of 0.5 mg dutasteride and 0.4 mg tamsulosin
Number of subjects: 742
Study 25565364 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting with protocol-defined initiation of tamsulosin therapy if symptoms did not improve (WW-All)
Number of subjects: 742
Study 23885709 — intervention group
Group type: COMPARATOR
Intervention: OVAL survey for estimating sun exposure
Number of subjects: 90
Study 23885709 — intervention group
Group type: EXPERIMENTAL
Intervention: Geraldton survey (gold standard) for estimating sun exposure
Number of subjects: 90
Study 23885709 — intervention group
Group type: COMPARATOR
Intervention: OVAL survey for estimating vitamin D exposure
Number of subjects: 90
Study 21775681 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (anti-CD20 monoclonal antibody), administered as four weekly doses.
Number of subjects: 0
Study 21775681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19030182 — intervention group
Group type: EXPERIMENTAL
Intervention: Darifenacin
Number of subjects: 375
Study 19030182 — intervention group
Group type: EXPERIMENTAL
Intervention: Darifenacin plus Behavioral Modification Program
Number of subjects: 375
Study 19030182 — intervention group
Group type: EXPERIMENTAL
Intervention: OAB-SAT-q
Number of subjects: 375
Study 17542980 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable pulsed light (VPL)
Number of subjects: 25
Study 17542980 — intervention group
Group type: COMPARATOR
Intervention: Light-emitting diode (LED)
Number of subjects: 25
Study 15447886 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory-specific satiety measured after ad libitum lunch
Number of subjects: 44
Study 15447886 — intervention group
Group type: EXPERIMENTAL
Intervention: Taste (sweet or savory)
Number of subjects: 44
Study 15447886 — intervention group
Group type: EXPERIMENTAL
Intervention: Appetite ratings after lunch
Number of subjects: 44
Study 11433853 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (mean dose, 8.6 mg)
Number of subjects: 997
Study 11433853 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam plus additional midazolam as needed (mean total dose, 12.2 mg)
Number of subjects: 997
Study 11433853 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (1.4 micrograms/kg) plus midazolam (mean dose, 5.7 mg)
Number of subjects: 997
Study 11433853 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (1.4 micrograms/kg), midazolam (mean dose, 5.8 mg) and methohexital as needed (mean dose, 61.0 mg)
Number of subjects: 997
Study 11433853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 997
Study 9730384 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous acetic acid injection (50% acetic acid)
Number of subjects: 60
Study 9730384 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous ethanol injection (absolute ethanol)
Number of subjects: 60
Study 8049833 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Number of subjects: 8
Study 8049833 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep fragmentation
Number of subjects: 8
Study 3885181 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 30
Study 3885181 — intervention group
Group type: COMPARATOR
Intervention: Ticarcillin and Tobramycin
Number of subjects: 30
Study 31904855 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG (0.4 g/kg/d) for five consecutive days
Number of subjects: 26
Study 31904855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 30257794 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeon control of fluoroscope activation
Number of subjects: 73
Study 30257794 — intervention group
Group type: COMPARATOR
Intervention: Technologist control of fluoroscope activation
Number of subjects: 73
Study 27538468 — intervention group
Group type: EXPERIMENTAL
Intervention: Miniaturized cardiopulmonary bypass systems
Number of subjects: 0
Study 27538468 — intervention group
Group type: COMPARATOR
Intervention: Traditional cardiopulmonary bypass systems
Number of subjects: 0
Study 24739906 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine mouth rinse
Number of subjects: 30
Study 24739906 — intervention group
Group type: COMPARATOR
Intervention: Combination mouth rinse (0.03% triclosan, 0.05% sodium fluoride, and 5% xylitol)
Number of subjects: 30
Study 23056361 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow breathing with biofeedback; n=15
Number of subjects: 46
Study 23056361 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow breathing without biofeedback; n=15
Number of subjects: 46
Study 23056361 — intervention group
Group type: COMPARATOR
Intervention: Control group; n=15
Number of subjects: 46
Study 20839152 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (4 mg)
Number of subjects: 160
Study 20839152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 18626028 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care intervention
Number of subjects: 64
Study 18626028 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 64
Study 17113780 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 30
Study 17113780 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 30
Study 17113780 — intervention group
Group type: COMPARATOR
Intervention: Both Diltiazem and Amiodarone
Number of subjects: 30
Study 15359583 — intervention group
Group type: EXPERIMENTAL
Intervention: 2, 5, 10, or 25 mg tadalafil
Number of subjects: 212
Study 15359583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study 11938824 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrase injection (DI)
Number of subjects: 64
Study 11938824 — intervention group
Group type: EXPERIMENTAL
Intervention: Acanthopanax injection (AI)
Number of subjects: 64
Study 11938824 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginaton injection (GI)
Number of subjects: 64
Study 11938824 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 64
Study 8957976 — intervention group
Group type: EXPERIMENTAL
Intervention: rocuronium 0.6 mg kg‐1
Number of subjects: 20
Study 8957976 — intervention group
Group type: COMPARATOR
Intervention: vecuronium 0.1 mg kg‐1
Number of subjects: 20
Study 1389316 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoglobulin (Endobulin, Immuno) administered intravenously at a dose of 100 mg/kg/week during the first 3 months, followed by 2 x 200 mg/kg/month during the 4th, 5th, and 6th months
Number of subjects: 60
Study 1389316 — intervention group
Group type: COMPARATOR
Intervention: No immunoglobulin administered
Number of subjects: 60
Study 3898410 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoxicam
Number of subjects: 0
Study 3898410 — intervention group
Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 0
Study 31800470 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin
Number of subjects: 11
Study 31800470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 30732583 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive interventions focused on treatment intensification and adherence improvement.
Number of subjects: 648
Study 30732583 — intervention group
Group type: COMPARATOR
Intervention: Control group based on randomized selection from the SIDIAP database.
Number of subjects: 648
Study 27443526 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra Virgin Olive Oil (EVOO), 50 ml daily for 3 weeks
Number of subjects: 23
Study 27443526 — intervention group
Group type: COMPARATOR
Intervention: Refined Olive Oil (ROO), 50 ml daily for 3 weeks
Number of subjects: 23
Study 27002934 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous rucaparib (intermittent dosing schedule)
Number of subjects: 44
Study 27002934 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rucaparib (across all six dose levels)
Number of subjects: 44
Study 24373376 — intervention group
Group type: EXPERIMENTAL
Intervention: PRK with adjuvant mitomycin-C (MMC)
Number of subjects: 13
Study 24373376 — intervention group
Group type: COMPARATOR
Intervention: Epithelial laser in situ keratomileusis (epi-LASIK)
Number of subjects: 13
Study 24373376 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PRK-MMC and epi-LASIK
Number of subjects: 13
Study 22868016 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.5 mg/kg (maximum of 8 mg)
Number of subjects: 100
Study 19324976 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 160
Study 19324976 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 160
Study 17507612 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (45 min, 5 days/week moderate-intensity sports/recreational exercise)
Number of subjects: 173
Study 17507612 — intervention group
Group type: COMPARATOR
Intervention: Stretching control group
Number of subjects: 173
Study 14961167 — intervention group
Group type: EXPERIMENTAL
Intervention: MDK-group (supplement with minerals and vitamin D plus vitamin K1)
Number of subjects: 181
Study 14961167 — intervention group
Group type: COMPARATOR
Intervention: MD-group (supplement with minerals and vitamin D)
Number of subjects: 181
Study 14961167 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 181
Study 14961167 — intervention group
Group type: COMPARATOR
Intervention: MD-group vs Placebo
Number of subjects: 181
Study 14961167 — intervention group
Group type: EXPERIMENTAL
Intervention: MDK-group vs Placebo
Number of subjects: 181
Study 14961167 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 181
Study 11903917 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 57
Study 11903917 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 57
Study 11903917 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 57
Study 9627208 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticonvulsant monotherapy (200mg CBZ, 500mg VPA, 100mg PHT)
Number of subjects: 23
Study 11224254 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 4mg
Number of subjects: 7
Study 11224254 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 2mg
Number of subjects: 7
Study 11224254 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (both doses)
Number of subjects: 7
Study 11224254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 3115662 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled carbon dioxide (CO2) at constant flow into a breathing circuit
Number of subjects: 11
Study 3115662 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled carbon dioxide (CO2) during exercise
Number of subjects: 11
Study 28421355 — intervention group
Group type: EXPERIMENTAL
Intervention: Elombe ('Champion') standard operating procedure (SOP)
Number of subjects: 36
Study 28421355 — intervention group
Group type: COMPARATOR
Intervention: No SOP (comparison)
Number of subjects: 36
Study 27225736 — intervention group
Group type: EXPERIMENTAL
Intervention: Balneotherapy (21 sessions of spa treatment with 34.8 °C thermomineral water, 5 days a week)
Number of subjects: 66
Study 27225736 — intervention group
Group type: COMPARATOR
Intervention: Education alone (control group)
Number of subjects: 66
Study 24722839 — intervention group
Group type: EXPERIMENTAL
Intervention: CHG‐containing adhesive film dressings
Number of subjects: 0
Study 24722839 — intervention group
Group type: COMPARATOR
Intervention: Non‐antimicrobial control film dressings
Number of subjects: 0
Study 24152852 — intervention group
Group type: EXPERIMENTAL
Intervention: K‐712 (phytonutrient), 1 tab twice a day for one week/month
Number of subjects: 122
Study 24152852 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole 200 mg orally once a week
Number of subjects: 122
Study 24152852 — intervention group
Group type: EXPERIMENTAL
Intervention: K‐712 (phytonutrient)
Number of subjects: 122
Study 24152852 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole
Number of subjects: 122
Study 20838286 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary mononuclear bone marrow cell (BMC) transplantation (1 × 10^8 cells)
Number of subjects: 73
Study 20838286 — intervention group
Group type: COMPARATOR
Intervention: Control group (similar patients without BMC transplantation)
Number of subjects: 73
Study 18546325 — intervention group
Group type: COMPARATOR
Intervention: (1)H‐MRS analysis pretreatment
Number of subjects: 17
Study 18546325 — intervention group
Group type: EXPERIMENTAL
Intervention: (1)H‐MRS analysis posttreatment (1 year) in hepatic patients
Number of subjects: 17
Study 18546325 — intervention group
Group type: EXPERIMENTAL
Intervention: (1)H‐MRS analysis posttreatment (1 year) in neurological patients
Number of subjects: 17
Study 18546325 — intervention group
Group type: EXPERIMENTAL
Intervention: (1)H‐MRS analysis during neurological deterioration
Number of subjects: 17
Study 18546325 — intervention group
Group type: EXPERIMENTAL
Intervention: (1)H‐MRS analysis during liver failure exacerbation
Number of subjects: 17
Study 17187094 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryopreserved bone tissue
Number of subjects: 10
Study 17187094 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone tissue preserved in 98% glycerol solution at room temperature
Number of subjects: 10
Study 17187094 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 10
Study 17187094 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiological analysis of 98% glycerol solution and bone fragments
Number of subjects: 10
Study 11865133 — intervention group
Group type: EXPERIMENTAL
Intervention: Entacapone treatment for 2 months
Number of subjects: 65
Study 10369080 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life assessment prior to recurrence
Number of subjects: 69
Study 10369080 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life assessment immediately after diagnosis of recurrence
Number of subjects: 69
Study 10369080 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life assessment at follow-up 6 months later
Number of subjects: 69
Study 10369080 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported physical symptoms
Number of subjects: 69
Study 8566940 — intervention group
Group type: EXPERIMENTAL
Intervention: Buflomedil
Number of subjects: 744
Study 8566940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 744
Study 2194280 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril treatment for 9 days in 15 patients with diabetic nephropathy
Number of subjects: 55
Study 2194280 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril treatment for 8 weeks in 40 patients with diabetic nephropathy
Number of subjects: 55
Study 2194280 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol treatment for 8 weeks in 40 patients with diabetic nephropathy
Number of subjects: 55
Study 2194280 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term treatment with captopril in patients with diabetic nephropathy
Number of subjects: 55
Study 2194280 — intervention group
Group type: COMPARATOR
Intervention: Furosemide treatment adjusted for blood-pressure control in both groups
Number of subjects: 55
Study 318049 — intervention group
Group type: EXPERIMENTAL
Intervention: Periocular injection of penicillin combined with multiple preoperative applications of topical chloramphenicol‐sulphadimidine
Number of subjects: 6618
Study 318049 — intervention group
Group type: COMPARATOR
Intervention: Topical chloramphenicol‐sulphadimidine
Number of subjects: 6618
Study 318049 — intervention group
Group type: COMPARATOR
Intervention: Periocular penicillin alone
Number of subjects: 6618
Study 31873859 — intervention group
Group type: EXPERIMENTAL
Intervention: Silodosin 8 mg once daily
Number of subjects: 169
Study 31873859 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg once daily
Number of subjects: 169